Celgene Patent on Revlimid to Be Reviewed on Bass Challenge

(Bloomberg) Hedge-fund manager Kyle Bass has persuaded a federal agency that a Celgene Corp. patent on the blood cancer drug Revlimid may be invalid. The U.S. Patent and Trademark Office on Tuesday said Bass’s Coalition for Affordable Drugs has a “reasonable likelihood” of success in his challenge to a patent that expires in 2018. A final decision in the case will come in about a year.“This patent is another ridiculous example of evergreening by Celgene,” Bass said. “How is this patentable and how can the patent office possibly facilitate Celgene raising pricing on Revlimid from about $25,000 when first released to now over $180,000? Celgene uses ridiculous patents like this.”

To read this article:

This entry was posted in Syndicated. Bookmark the permalink.

Leave a Reply